Cantel Medical Corp. (NYSE:CMD) Chairman Charles M. Diker sold 20,500 shares of the stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $99.15, for a total transaction of $2,032,575.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Cantel Medical Corp. (CMD) traded down 0.04% on Wednesday, reaching $99.04. 151,407 shares of the company’s stock were exchanged. The stock has a market capitalization of $4.11 billion, a P/E ratio of 57.92 and a beta of 1.25. The firm’s 50 day moving average is $82.95 and its 200 day moving average is $77.37. Cantel Medical Corp. has a 1-year low of $68.19 and a 1-year high of $99.83.

Cantel Medical Corp. (NYSE:CMD) last issued its quarterly earnings results on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.02. The firm had revenue of $205.50 million for the quarter, compared to analysts’ expectations of $200.32 million. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. Analysts expect that Cantel Medical Corp. will post $2.34 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/cantel-medical-corp-cmd-chairman-sells-2032575-00-in-stock.html.

A number of equities research analysts recently commented on the stock. Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price objective on the stock in a research note on Wednesday, August 2nd. Zacks Investment Research raised shares of Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a research note on Tuesday, August 1st. Benchmark Co. cut shares of Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a research note on Thursday, June 8th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Cantel Medical Corp. has an average rating of “Hold” and an average price target of $91.67.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Globeflex Capital L P purchased a new position in Cantel Medical Corp. in the 2nd quarter worth about $114,000. Integrated Investment Consultants LLC purchased a new position in Cantel Medical Corp. in the 2nd quarter worth about $161,000. LS Investment Advisors LLC purchased a new position in Cantel Medical Corp. in the 2nd quarter worth about $172,000. Airain ltd purchased a new position in Cantel Medical Corp. in the 2nd quarter worth about $201,000. Finally, Punch & Associates Investment Management Inc. purchased a new position in Cantel Medical Corp. in the 2nd quarter worth about $212,000. 83.79% of the stock is currently owned by hedge funds and other institutional investors.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.